ArticleInternational journal of molecular sciences2020
3D Bioprinted Vascularized Tumour for Drug Testing.
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Advances in Engineering Human Tissue Models.Frontiers in bioengineering and biotechnology · 2020Pooled it
- Biomimetic Scaffold-Based 3D Models for Decoding Cancer Biology and Advancing Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Acoustic Tweezers-Assisted Biomaterial Molding in Petri Dishes (TAMP) for Engineering Glioma Tissues With Controlled Cellular and Extracellular Matrix Architectures.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Modeling cancer with bacteria-integrated tumor microenvironments using biomaterials: Emerging concepts and opportunities.Materials today. Bio · 2026Review
- 3D bioprinting for cancer modeling and drug screening.Biomarker research · 2026Review
- Photoacoustic microscopy reveals deep angiogenic responses in 3D bioprinted tumor-vessel models.Microsystems & nanoengineering · 2026Article
- 3D bioprinting of cell-laden constructs: technologies, bioink design, and biomedical applications.Biomedical materials (Bristol, England) · 2025Review
- Imaging Sensing of Cadmium-Induced Single Cancer Stem Cells in Tumor Spheroid Fabricated by 3D Bioprinting.ACS applied materials & interfaces · 2025Article
- Bioprinting for drug screening: A path toward reducing animal testing or redefining preclinical research?Bioactive materials · 2025Review
- Bioprinting of GelMA-Based Hydrogels to Aid in Creation of Biomimetic 3D Models for Glioblastoma.Micromachines · 2025Article
- Getting Blood out of a Stone: Vascularization via Spheroids and Organoids in 3D Bioprinting.Cells · 2025Review
- Recent advances in 3D printing applications for CNS tumours.European journal of medical research · 2025Review
- Advances in Drug Delivery Integrated with Regenerative Medicine: Innovations, Challenges, and Future Frontiers.Pharmaceutics · 2025Review
- Extrusion bioprinting: meeting the promise of human tissue biofabrication?Progress in biomedical engineering (Bristol, England) · 2025Review
- Cutting-edge 3D printing in immunosensor design for early cancer detection.Mikrochimica acta · 2024Review
- Recapitulating Glioma Stem Cell Niches Using 3D Spheroid Models for Glioblastoma Research.Biosensors · 2024Review
- 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications.ACS omega · 2024Review
- Tumoroids, a valid preclinical screening platform for monitoring cancer angiogenesis.Stem cell research & therapy · 2024Review
- A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth.Advanced healthcare materials · 2024Article
- Advancement in Cancer Vasculogenesis Modeling through 3D Bioprinting Technology.Biomimetics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
An in vitro screening system for anti-cancer drugs cannot exactly reflect the efficacy of drugs in vivo, without mimicking the tumour microenvironment (TME), which comprises cancer cells interacting with blood vessels and fibroblasts. Additionally, the tumour size should be controlled to obtain reliable and quantitative drug responses. Herein, we report a bioprinting method for recapitulating the TME with a controllable spheroid size. The TME was constructed by printing a blood vessel layer consisting of fibroblasts and endothelial cells in gelatine, alginate, and fibrinogen, followed by seeding multicellular tumour spheroids (MCTSs) of glioblastoma cells (U87 MG) onto the blood vessel layer. Under MCTSs, sprouts of blood vessels were generated and surrounding MCTSs thereby increasing the spheroid size. The combined treatment involving the anti-cancer drug temozolomide (TMZ) and the angiogenic inhibitor sunitinib was more effective than TMZ alone for MCTSs surrounded by blood vessels, which indicates the feasibility of the TME for in vitro testing of drug efficacy. These results suggest that the bioprinted vascularized tumour is highly useful for understanding tumour biology, as well as for in vitro drug testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.